Answers are grounded in this paper and cite their sources.
The field of fluoroquinolone research is rapidly expanding. Bacterial targets are constantly changing to meet the demands of resistance. At present, new compounds are targeting respiratory pathogens, such as Streptococcus pneumoniae. However, problems such as phototoxicity, cardiotoxicity and CNS disturbances must be overcome. New promising fluoroquinolones include: HSR 903, LB 20304 and BAY 12-8039. Research in the field of mycobacteria, especially for Mycobacterium tuberculosis, is also underway.
No takes yet. Share an insight, caveat, or question.
A. Bryskier (1997) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: